shutterstock_1891094320_guteksk7

guteksk7 / Shutterstock.com

14 July 2022Americas

Moderna, Pfizer face escalating COVID vaccine patent suits

New lawsuit comes months after the pair were accused of infringing lipid nanoparticle technology.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Alnylam says Moderna used patented tech to make vaccine

22 March 2022 Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.

CureVac sues BioNTech over mRNA technology

7 July 2022 Germany-based CureVac has accused BioNTech of infringing four patents related to messenger ribonucleic acid technology.

Vaccine makers hit back against patent claims

28 July 2022 German biotech and its US big pharma partner file counter complaint | Under-fire pair say they didn’t infringe patents | Claims reject earlier suit as an attempt to profit through legal threats.

More on this story

Alnylam says Moderna used patented tech to make vaccine

22 March 2022 Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.

CureVac sues BioNTech over mRNA technology

7 July 2022 Germany-based CureVac has accused BioNTech of infringing four patents related to messenger ribonucleic acid technology.

Vaccine makers hit back against patent claims

28 July 2022 German biotech and its US big pharma partner file counter complaint | Under-fire pair say they didn’t infringe patents | Claims reject earlier suit as an attempt to profit through legal threats.

More on this story

Alnylam says Moderna used patented tech to make vaccine

22 March 2022 Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.

CureVac sues BioNTech over mRNA technology

7 July 2022 Germany-based CureVac has accused BioNTech of infringing four patents related to messenger ribonucleic acid technology.

Vaccine makers hit back against patent claims

28 July 2022 German biotech and its US big pharma partner file counter complaint | Under-fire pair say they didn’t infringe patents | Claims reject earlier suit as an attempt to profit through legal threats.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool

USPTO clarifies AI's role in patent eligibility